Kiromic BioPharma Inc.
5
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
80.0%
4 terminated/withdrawn out of 5 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Role: lead
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Role: lead
Consolidation Therapy in Patients With Hematologic Malignancies
Role: lead
Consolidation Therapy in Patients With Metastatic Solid Malignancies
Role: lead
Therapy for Progressive and/or Refractory Hematologic Malignancies
Role: lead
All 5 trials loaded